In Q1 2026, Apollomics obtained a critical $2 million unsecured bridge financing from its CEO, facilitating ongoing development of its lead clinical-stage oncology candidate, vebreltinib. The financing, convertible into equity at a discount upon a future $10 million+ equity raise, underscores the company's persistent liquidity challenges amid heavy operating losses. Apollomics operates primarily via licensing deals and collaborations in Asia while focusing on treatment-resistant cancers with proprietary drug candidates. Its growth path hinges on trial outcomes, further financing rounds, and successful partnership extensions within a competitive and highly regulated biotech environment.